Solvonis Therapeutics PLC (LSE:SVNS) has appointed Dr Renata Crome as its new independent director, bringing four decades of experience in drug development and regulatory approval.
Her career includes 30 years at pharmaceutical giant Roche, where she played a key role in advancing over 100 therapies from early research to clinical trials.
She was instrumental in prioritising blockbuster drugs such as Avastin and Tamiflu, which went on to generate billions in sales.
Crome is currently a consultant for Novo Nordisk, the maker of Ozempic, and has previously led a UK government-backed Covid-19 treatments programme.
Chair Dennis Purcell said: "Her extensive experience in drug development, regulatory affairs, and commercial strategy, combined with her governance expertise, will be invaluable as Solvonis continues to advance its innovative therapies in the mental health and addiction spaces."